Latest Press Releases & News

Regcell Inc. has raised $66 million in new financing and Japanese government support to move its Nobel-linked regulatory T-cell (Treg) platform toward the clinic, advancing…

RegCell has closed a $66 million funding round combining a fully subscribed $44 million Series A financing and a $22 million non-dilutive grant from Japan’s…

Combined financing will enable IND submission and advance RegCell’s next-generation epigenetic reprogramming platform into a second autoimmune indication through Phase 2 as proof of concept.

In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg)…

Dr. Mike McCullar, CEO of RegCell, is developing a novel cell therapy to treat autoimmune diseases that specifically addresses the loss of tolerance, in which…

Kincell Bio has announced a new collaboration with RegCell, a biotechnology company developing an immune tolerance platform based on epigenetically reprogrammed regulatory T cells. Under…

Nobel Prize winner Shimon Sakaguchi, a pioneer in regulatory T cell (Treg) biology, discusses the path from early observations to reprogrammed cell therapies for autoimmune…

Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and…

Asia’s biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities. Japan, after a period…

Shimon Sakaguchi shared the 2025 Nobel Prize in Physiology or Medicine for his identification of regulatory T cells that suppress autoimmune responses. His work laid…

While several companies await regulatory approval decisions on their cell therapies in Japan, BioCardia proceeds with discussions on an NDA filing and Innovacel readies an…

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.